Novartis this week scored a victory for...

...its bestselling multiple sclerosis (MS) therapy, Gilenya, winning a temporary injunction against generic competitor launches from Dr. Reddy’s Laboratories and Mylan. The U.S. district judge in Delaware said the generic launches would jeopardize Novartis' current patent litigation for the drug. For the treatment of MS, Gilenya currently holds preferred status for 13% of covered lives, growing to 48% with prior authorization and/or step therapy.  

SOURCE: MMIT Analytics, as of 6/26/19